AMPHETAMINES HAVE A HIGH POTENTIAL FOR ABUSE. ADMINISTRATION OF AMPHETAMINES FOR PROLONGED PERIODS OF TIME MAY LEAD TO DRUG DEPENDENCE AND MUST BE AVOIDED. PARTICULAR ATTENTION SHOULD BE PAID TO THE POSSIBILITY OF SUBJECTS OBTAINING AMPHETAMINES FOR NON-THERAPEUTIC USE OR DISTRIBUTION TO OTHERS, AND THE DRUGS SHOULD BE PRESCRIBED OR DISPENSED SPARINGLY. MISUSE OF AMPHETAMINES MAY CAUSE SUDDEN DEATH AND SERIOUS CAR...
ProCentra ® (dextroamphetamine sulfate) Oral Solution is indicated in: Narcolepsy As an integral part of a total treatment program that typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in pediatric patients (ages 3 years to 16 years) with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: Moderate to severe d...
Amphetamines should be administered at the lowest effective dosage and dosage should be individually adjusted. Late evening doses should be avoided because of the resulting insomnia. Usual dose is 5 mg to 60 mg per day in divided doses, depending on the individual patient response. Narcolepsy seldom occurs in children under 12 years of age; however, when it does, ProCentra ® (dextroamphetamine sulfate) Oral Soluti...
www.fda.gov/medwatch
www.fsclabs.comCII
WARNING
Rx Only
AMPHETAMINES HAVE A HIGH POTENTIAL FOR ABUSE. ADMINISTRATION OF AMPHETAMINES FOR PROLONGED PERIODS OF TIME MAY LEAD TO DRUG DEPENDENCE AND MUST BE AVOIDED. PARTICULAR ATTENTION SHOULD BE PAID TO THE POSSIBILITY OF SUBJECTS OBTAINING AMPHETAMINES FOR NON-THERAPEUTIC USE OR DISTRIBUTION TO OTHERS, AND THE DRUGS SHOULD BE PRESCRIBED OR DISPENSED SPARINGLY.
MISUSE OF AMPHETAMINES MAY CAUSE SUDDEN DEATH AND SERIOUS CARDIOVASCULAR ADVERSE EVENTS.
Dextroamphetamine sulfate is the dextro isomer of the compound d,l-amphetamine sulfate, a sympathomimetic amine of the amphetamine group. Chemically, dextroamphetamine is d-alpha-methylphenethylamine, and is present in all forms of dextroamphetamine sulfate as the neutral sulfate.
Structural Formula:
ProCentra® (dextroamphetamine sulfate) is a colorless, bubble gum flavored oral solution. Each teaspoonful (5 mL) of ProCentra ® (dextroamphetamine sulfate) Oral Solution contains 5 mg of dextroamphetamine sulfate. Inactive ingredients consist of benzoic acid, citric acid anhydrous, purified water, sodium citrate hydrous, sodium saccharin, sorbitol solution, and artificial bubble gum flavor.
Amphetamines are noncatecholamine, sympathomimetic amines with CNS stimulant activity. Peripheral actions include elevations of systolic and diastolic blood pressures and weak bronchodilator and respiratory stimulant action.
There is neither specific evidence that clearly establishes the mechanism whereby amphetamines produce mental and behavioral effects in children, nor conclusive evidence regarding how these effects relate to the condition of the central nervous system.
Ingestion of 10 mg of dextroamphetamine sulfate in oral solution form by healthy volunteers produced an average peak dextroamphetamine blood level of 33.2 ng/mL. The half-life was 11.75 hours. The average urinary recovery was 38% in 48 hours.
In 12 healthy subjects, the rate and extent of dextroamphetamine absorption were similar following administration of the sustained release capsule formulation in the fed (58 to 75 gm fat) and fasted state.
ProCentra® (dextroamphetamine sulfate) Oral Solution is indicated in:
Narcolepsy
As an integral part of a total treatment program that typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in pediatric patients (ages 3 years to 16 years) with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: Moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. The diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. Nonlocalizing (soft) neurological signs, learning disability, and abnormal EEG may or may not be present, and a diagnosis of central nervous system dysfunction may or may not be warranted.
Advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism, known hypersensitivity or idiosyncrasy to the sympathomimetic amines, glaucoma.
Agitated states.
Patients with a history of drug abuse.
During or within 14 days following the administration of monoamine oxidase inhibitors (hypertensive crisis may result).
Sudden death has been reported in association with CNS stimulant treatment at usual doses in children and adolescents with structural cardiac abnormalities or other serious heart problems. Although some serious heart problems alone carry an increased risk of sudden death, stimulant products generally should not be used in children or adolescents with known serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, or other serious cardiac problems that may place them at increased vulnerability to the sympathomimetic effects of a stimulant drug.
Sudden deaths, stroke, and myocardial infarction have been reported in adults taking stimulant drugs at usual doses for ADHD. Although the role of stimulants in these adult cases is also unknown, adults have a greater likelihood than children of having serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems. Adults with such abnormalities should also generally not be treated with stimulant drugs (see CONTRAINDICATIONS).
Stimulant medications cause a modest increase in average blood pressure (about 2-4 mmHg) and average heart rate (about 3-6 bpm), and individuals may have larger increases. While the mean changes alone would not be expected to have short term consequences, all patients should be monitored for larger changes in heart rate and blood pressure. Caution is indicated in treating patients whose underlying medical conditions might be compromised by increases in blood pressure or heart rate, e.g., those with pre-existing hypertension, heart failure, recent myocardial infarction, or ventricular arrhythmia (see CONTRAINDICATIONS).
Children, adolescents, or adults who are being considered for treatment with stimulant medications should have a careful history (including assessment for a family history of sudden death or ventricular arrhythmia) and physical exam to assess for the presence of cardiac disease, and should receive further cardiac evaluation if findings suggest such disease (e.g., electrocardiogram and echocardiogram). Patients who develop symptoms such as exertional chest pain, unexplained syncope, or other symptoms suggestive of cardiac disease during stimulant treatment should undergo a prompt cardiac evaluation.
Administration of stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with pre-existing psychotic disorder.
Particular care should be taken in using stimulants to treat ADHD in patients with comorbid bipolar disorder because of concern for possible induction of a mixed/manic episode in such patients. Prior to initiating treatment with stimulant, patients with comorbid depressive symptoms should be adequately screened to determine if they are at risk for bipolar disorder; such screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and depression.
Treatment emergent psychotic or manic symptoms, e.g., hallucinations, delusional thinking, or mania in children and adolescents without a prior history of psychotic illness or mania can be caused by stimulants at usual doses. If such symptoms occur, consideration should be given to a possible causal role of the stimulant, and discontinuation of treatment may be appropriate. In a pooled analysis of multiple short-term, placebo-controlled studies, such symptoms occurred in about 0.1% (4 patients with events out of 3,482 exposed to methylphenidate or amphetamine for several weeks at usual doses) of stimulant-treated patients compared to 0 in placebo-treated patients.
Aggressive behavior or hostility is often observed in children and adolescents with ADHD, and has been reported in clinical trials and the postmarketing experience of some medications indicated for the treatment of ADHD. Although there is no systematic evidence that stimulants cause aggressive behavior or hostility, patients beginning treatment for ADHD should be monitored for the appearance of, or worsening of, aggressive behavior or hostility.
Careful follow-up of weight and height in children ages 7 to 10 years who were randomized to either methylphenidate or non-medication treatment groups over 14 months, as well as in naturalistic subgroups of newly methylphenidate-treated and non-medication treated children over 36 months (to the ages of 10 to 13 years), suggests that consistently medicated children (i.e., treatment for 7 days per week throughout the year) have a temporary slowing in growth rate (on average, a total of about 2 cm less growth in height and 2.7 kg less growth in weight over 3 years), without evidence of growth rebound during this period of development. Published data are inadequate to determine whether chronic use of amphetamines may cause a similar suppression of growth, however, it is anticipated that they likely have this effect as well. Therefore, growth should be monitored during treatment with stimulants, and patients who are not growing or gaining height or weight as expected may need to have their treatment interrupted.
There is some clinical evidence that stimulants may lower the convulsive threshold in patients with prior history of seizures, in patients with prior EEG abnormalities in absence of seizures, and, very rarely, in patients without a history of seizures and no prior EEG evidence of seizures. In the presence of seizures, the drug should be discontinued.
Difficulties with accommodation and blurring of vision have been reported with stimulant treatment.
The least amount feasible should be prescribed or dispensed at one time in order to minimize the possibility of overdosage.
Amphetamines may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or vehicles; the patient should therefore be cautioned accordingly.
Prescribers or other health professionals should inform patients, their families, and their caregivers about the benefits and risks associated with treatment with dextroamphetamine and should counsel them in its appropriate use. A patient Medication Guide is available for ProCentra ® (dextroamphetamine sulfate) Oral Solution. The prescriber or health professional should instruct patients, their families, and their caregivers to read the Medication Guide and should assist them in understanding its contents. Patients should be given the opportunity to discuss the contents of the Medication Guide and to obtain answers to any questions they may have. The complete text of the Medication Guide is reprinted at the end of this document.
Gastrointestinal acidifying agents (guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines. Urinary acidifying agents (ammonium chloride, sodium acid phosphate, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion. Both groups of agents lower blood levels and efficacy of amphetamines.
Adrenergic blockers are inhibited by amphetamines.
Gastrointestinal alkalinizing agents (sodium bicarbonate, etc.) increase absorption of amphetamines. Urinary alkalinizing agents (acetazolamide, some thiazides) increase the concentration of the non-ionized species of the amphetamine molecule, thereby decreasing urinary excretion. Both groups of agents increase blood levels and therefore potentiate the actions of amphetamines.
Amphetamines may enhance the activity of tricyclic or sympathomimetic agents; d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain; cardiovascular effects can be potentiated.
MAOI antidepressants, as well as a metabolite of furazolidone, slow amphetamine metabolism. This slowing potentiates amphetamines, increasing their effect on the release of norepinephrine and other monoamines from adrenergic nerve endings; this can cause headaches and other signs of hypertensive crisis. A variety of neurological toxic effects and malignant hyperpyrexia can occur, sometimes with fatal results.
Amphetamines may counteract the sedative effect of antihistamines.
Amphetamines may antagonize the hypotensive effects of antihypertensives.
Chlorpromazine blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines, and can be used to treat amphetamine poisoning.
Amphetamines may delay intestinal absorption of ethosuximide.
Haloperidol blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines.
The stimulatory effects of amphetamines may be inhibited by lithium carbonate.
Amphetamines potentiate the analgesic effect of meperidine.
Urinary excretion of amphetamines is increased, and efficacy is reduced, by acidifying agents used in methenamine therapy.
Amphetamines enhance the adrenergic effect of norepinephrine.
Amphetamines may delay intestinal absorption of phenobarbital; coadministration of phenobarbital may produce a synergistic anticonvulsant action.
Amphetamines may delay intestinal absorption of phenytoin; co-administration of phenytoin may produce a synergistic anticonvulsant action.
In cases of propoxyphene overdosage, amphetamine CNS stimulation is potentiated and fatal convulsions can occur.
Amphetamines inhibit the hypotensive effect of veratrum alkaloids.
Amphetamines can cause a significant elevation in plasma corticosteroid levels. This increase is greatest in the evening.
Amphetamines may interfere with urinary steroid determinations.
Mutagenicity studies and long-term studies in animals to determine the carcinogenic potential of dextroamphetamine sulfate have not been performed.
Dextroamphetamine sulfate has been shown to have embryotoxic and teratogenic effects when administered to A/Jax mice and C57BL mice in doses approximately 41 times the maximum human dose. Embryotoxic effects were not seen in New Zealand white rabbits given the drug in doses 7 times the human dose nor in rats given 12.5 times the maximum human dose. While there are no adequate and well-controlled studies in pregnant women, there has been one report of severe congenital bony deformity, tracheoesophageal fistula, and anal atresia (VATER association) in a baby born to a woman who took dextroamphetamine sulfate with lovastatin during the first trimester of pregnancy. Dextroamphetamine sulfate should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Infants born to mothers dependent on amphetamines have an increased risk of premature delivery and low birth weight. Also, these infants may experience symptoms of withdrawal as demonstrated by dysphoria, including agitation, and significant lassitude.
Amphetamines are excreted in human milk. Mothers taking amphetamines should be advised to refrain from nursing.
Long-term effects of amphetamines in pediatric patients have not been well established.
Amphetamines are not recommended for use in pediatric patients under 3 years of age with Attention Deficit Disorder with Hyperactivity described under INDICATIONS AND USAGE.
Clinical experience suggests that in psychotic children, administration of amphetamines may exacerbate symptoms of behavior disturbance and thought disorder.
Amphetamines have been reported to exacerbate motor and phonic tics and Tourette's syndrome. Therefore, clinical evaluation for tics and Tourette's syndrome in children and their families should precede use of stimulant medications.
Data are inadequate to determine whether chronic administration of amphetamines may be associated with growth inhibition; therefore, growth should be monitored during treatment.
Drug treatment is not indicated in all cases of Attention Deficit Disorder with Hyperactivity and should be considered only in light of the complete history and evaluation of the child. The decision to prescribe amphetamines should depend on the physician's assessment of the chronicity and severity of the child's symptoms and their appropriateness for his or her age. Prescription should not depend solely on the presence of one or more of the behavioral characteristics.
When these symptoms are associated with acute stress reactions, treatment with amphetamines is usually not indicated.
To report SUSPECTED ADVERSE REACTIONS, contact FSC Laboratories, Inc. at 1-866-764-7822, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Cardiovascular: Palpitations, tachycardia, elevation of blood pressure. There have been isolated reports of cardiomyopathy associated with chronic amphetamine use.
Central Nervous System: Psychotic episodes at recommended doses (rare), overstimulation, restlessness, dizziness, insomnia, euphoria, dyskinesia, dysphoria, tremor, headache, exacerbation of motor and phonic tics and Tourette's syndrome.
Gastrointestinal: Dryness of the mouth, unpleasant taste, diarrhea, constipation, other gastrointestinal disturbances. Anorexia and weight loss may occur as undesirable effects.
Allergic: Urticaria.
Endocrine: Impotence, changes in libido.
Dextroamphetamine sulfate is a Schedule II controlled substance.
Amphetamines have been extensively abused. Tolerance, extreme psychological dependence and severe social disability have occurred. There are reports of patients who have increased the dosage to many times that recommended. Abrupt cessation following prolonged high dosage administration results in extreme fatigue and mental depression; changes are also noted on the sleep EEG.
Manifestations of chronic intoxication with amphetamines include severe dermatoses, marked insomnia, irritability, hyperactivity and personality changes. The most severe manifestation of chronic intoxication is psychosis, often clinically indistinguishable from schizophrenia. This is rare with oral amphetamines.
Individual patient response to amphetamines varies widely. While toxic symptoms occasionally occur as an idiosyncrasy at doses as low as 2 mg, they are rare with doses of less than 15 mg; 30 mg can produce severe reactions, yet doses of 400 to 500 mg are not necessarily fatal.
In rats, the oral LD50 of dextroamphetamine sulfate is 96.8 mg/kg.
Manifestations of acute overdosage with amphetamines include restlessness, tremor, hyperreflexia, rhabdomyolysis, rapid respiration, hyperpyrexia, confusion, assaultiveness, hallucinations, panic states.
Fatigue and depression usually follow the central stimulation.
Cardiovascular effects include arrhythmias, hypertension or hypotension and circulatory collapse.
Gastrointestinal symptoms include nausea, vomiting, diarrhea and abdominal cramps.
Fatal poisoning is usually proceeded by convulsions and coma.
Consult with a Certified Poison Control Center for up-to-date guidance and advice. Management of acute amphetamine intoxication is largely symptomatic and includes gastric lavage, administration of activated charcoal, administration of a cathartic, and sedation. Experience with hemodialysis or peritoneal dialysis is inadequate to permit recommendation in this regard. Acidification of the urine increases amphetamine excretion, but is believed to increase risk of acute renal failure if myoglobinuria is present. If acute, severe hypertension complicates amphetamine overdosage, administration of intravenous phentolamine (Bedford Laboratories) has been suggested. However, a gradual drop in blood pressure will usually result when sufficient sedation has been achieved.
Chlorpromazine antagonizes the central stimulant effects of amphetamines and can be used to treat amphetamine intoxication.
Amphetamines should be administered at the lowest effective dosage and dosage should be individually adjusted. Late evening doses should be avoided because of the resulting insomnia.
Usual dose is 5 mg to 60 mg per day in divided doses, depending on the individual patient response.
Narcolepsy seldom occurs in children under 12 years of age; however, when it does, ProCentra ® (dextroamphetamine sulfate) Oral Solution may be used. The suggested initial dose for patients aged 6 to 12 is 5 mg daily; daily dose may be raised in increments of 5 mg at weekly intervals until optimal response is obtained. In patients 12 years of age and older, start with 10 mg daily; daily dosage may be raised in increments of 10 mg at weekly intervals until optimal response is obtained. If bothersome adverse reactions appear (e.g., insomnia or anorexia), dosage should be reduced. Give first dose on awakening; additional doses (1 or 2) at intervals of 4 to 6 hours.
Not recommended for pediatric patients under 3 years of age.
In pediatric patients from 3 to 5 years of age, start with 2.5 mg daily; daily dosage may be raised in increments of 2.5 mg at weekly intervals until optimal response is obtained.
In pediatric patients 6 years of age and older, start with 5 mg once or twice daily; daily dosage may be raised in increments of 5 mg at weekly intervals until optimal response is obtained. Only in rare cases will it be necessary to exceed a total of 40 mg per day.
Give first dose on awakening; additional doses (1 or 2) at intervals of 4 to 6 hours.
Where possible, drug administration should be interrupted occasionally to determine if there is a recurrence of behavioral symptoms sufficient to require continued therapy.
ProCentra® (dextroamphetamine sulfate) Oral Solution 5 mg/5 mL is a colorless, bubble gum flavored oral solution, available in containers of 16 fluid ounces, NDC 13551-701-05.
Store at 20° – 25°C (68° – 77°F) (See USP Controlled Room Temperature). Dispense in a tight, light resistant container.
ProCentra® (dextroamphetamine sulfate)
Oral Solution, 5 mg/5 mL CII
Please read the Medication Guide that comes with ProCentra® (dextroamphetamine sulfate) Oral Solution before you or your child starts taking it and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking to your doctor about your or your child's treatment with ProCentra®.
What is the most important information I should know about ProCentra®?
The following have been reported with use of ProCentra® and other stimulant medicines.
1. Heart-related problems:
Tell your doctor if you or your child have any heart problems, heart defects, high blood pressure, or a family history of these problems.
Your doctor should check you or your child carefully for heart problems before starting ProCentra®.
Your doctor should check your or your child's blood pressure and heart rate regularly during treatment with ProCentra®.
Call your doctor right away if you or your child has any signs of heart problems such as chest pain, shortness of breath, or fainting while taking ProCentra®.
2. Mental (Psychiatric) problems:
All Patients
Children and Teenagers
Tell your doctor about any mental problems you or your child have, or about a family history of suicide, bipolar illness, or depression.
Call your doctor right away if you or your child have any new or worsening mental symptoms or problems while taking ProCentra®, especially seeing or hearing things that are not real, believing things that are not real, or are suspicious.
What is ProCentra®?
ProCentra® is a central nervous system stimulant prescription medicine. It is used for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD). ProCentra® may help increase attention and decrease impulsiveness and hyperactivity in patients with ADHD.
ProCentra® should be used as a part of a total treatment program for ADHD that may include counseling or other therapies.
ProCentra® is also used in the treatment of a sleep disorder called narcolepsy.
ProCentra® (dextroamphetamine sulfate) Oral Solution is a federally controlled substance (CII) because it can be abused or lead to dependence.
Keep ProCentra® in a safe place to prevent misuse and abuse. Selling or giving away ProCentra® may harm others, and is against the law.
Tell your doctor if you or your child have (or have a family history of) ever abused or been dependent on alcohol, prescription medicines or street drugs.
Who should not take ProCentra®?
ProCentra® should not be taken if you or your child:
ProCentra® is not recommended for use in children less than 3 years old.
ProCentra® may not be right for you or your child. Before starting ProCentra® tell your or your child's doctor about all health conditions (or a family history of) including:
Tell your doctor if you or your child is pregnant, planning to become pregnant, or breastfeeding.
Can ProCentra® be taken with other medicines?
Tell your doctor about all of the medicines that you or your child take including prescription and nonprescription medicines, vitamins, and herbal supplements.
ProCentra® and some medicines may interact with each other and cause serious side effects. Sometimes the doses of other medicines will need to be adjusted while taking ProCentra®.
Your doctor will decide whether ProCentra® can be taken with other medicines.
Especially tell your doctor if you or your child takes:
Know the medicines that you or your child takes. Keep a list of your medicines with you to show your doctor and pharmacist.
Do not start any new medicine while taking ProCentra® without talking to your doctor first.
How should ProCentra® be taken?
What are possible side effects of ProCentra®?
See "What is the most important information I should know about ProCentra®?" for information on reported heart and mental problems.
Other serious side effects include:
Common side effects include:
|
|
|
ProCentra® may affect you or your child's ability to drive or do other dangerous activities.
Talk to your doctor if you or your child has side effects that are bothersome or do not go away.
This is not a complete list of possible side effects. Ask your doctor or pharmacist for more information.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store ProCentra®?
General information about ProCentra®
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use ProCentra® for a condition for which it was not prescribed. Do not give ProCentra® to other people, even if they have the same condition. It may harm them and it is against the law.
This Medication Guide summarizes the most important information about ProCentra®. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about ProCentra® that was written for healthcare professionals. For more information about ProCentra®, please contact FSC Laboratories, Inc. at 1-704-941-2500.
What are the ingredients in ProCentra®?
Active Ingredient: dextroamphetamine sulfate
Inactive Ingredients: benzoic acid, citric acid anhydrous, purified water, sodium citrate hydrous, sodium saccharin, sorbitol solution, and artificial bubble gum flavor.
This Medication Guide has been approved by the U.S. Food and Drug Administration.
Distributed By:
FSC Laboratories, Inc.
Charlotte, NC 28210 USAwww.fsclabs.com
Revised: June 2010
NDC 13551-701-05
ProCentra®
(dextroamphetamine sulfate)
Oral Solution
5mg/5mL
CII
Rx only
PHARMACIST:
Dispense Medication Guide
with the Drug Product.
16 fl. oz. (473 mL)
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 13551-701-05 | 2023-01-12 | C162847 | 48780-1 | 9d75b9d0-5878-f424-e053-dadaa90a57ce | ProCentra ® (dextroamphetamine sulfate) Oral Solution 5 mg/5 mL |
| 13551-701-05 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-5878-f424-e053-dadaa90a57ce | ProCentra ® (dextroamphetamine sulfate) Oral Solution 5 mg/5 mL |
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 13551-701-05 | ML - Milliliter | 13551-701 | f6c971b2-bb93-4889-8db6-3cb30f1f8231 | 1 | 2012-07-24 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| dextroamphetamine sulfate | ACTIVE INGREDIENT | JJ768O327N | 1 | |
| dextroamphetamine | ACTIVE MOIETY | TZ47U051FI | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 13551-701 | 13551-701-05 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| dextroamphetamine sulfate | JJ768O327N | ACTIB |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A040776-001 | DEXTROAMPHETAMINE SULFATE | DEXTROAMPHETAMINE SULFATE | 5MG/5ML | SOLUTION / ORAL | AA | RS | 2008-01-29 |
| Application-product | TE code |
|---|---|
| A040776-001 | AA |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A040776-001 | DEXTROAMPHETAMINE SULFATE | 5MG/5ML | SOLUTION / ORAL | AA | RS | 2008-01-29 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | A040776-001 | DEXTROAMPHETAMINE SULFATE | 5MG/5ML | SOLUTION / ORAL | AA | RS | 2008-01-29 | caaa826d4ba7… |
| 2026-02-19 14:30 UTC | 2026-02 | A040776-001 | DEXTROAMPHETAMINE SULFATE | 5MG/5ML | SOLUTION / ORAL | AA | RS | 2008-01-29 | 011fe1cb6892… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A040776-001 | DEXTROAMPHETAMINE SULFATE | 5MG/5ML | SOLUTION / ORAL | AA | RS | 2008-01-29 | 31067a03dcf5… |
| 2025-08-23 18:47 UTC | 2025-08 | A040776-001 | DEXTROAMPHETAMINE SULFATE | 5MG/5ML | SOLUTION / ORAL | AA | RS | 2008-01-29 | 6a471c1ec25d… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A040776-001 | DEXTROAMPHETAMINE SULFATE | 5MG/5ML | SOLUTION / ORAL | AA | RS | 2008-01-29 | fd3edfee7708… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A040776-001 | DEXTROAMPHETAMINE SULFATE | 5MG/5ML | SOLUTION / ORAL | AA | RS | 2008-01-29 | b8a1b40f171c… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A040776-001 | DEXTROAMPHETAMINE SULFATE | 5MG/5ML | SOLUTION / ORAL | AA | RS | 2008-01-29 | 03ed91905a0d… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A040776-001 | DEXTROAMPHETAMINE SULFATE | 5MG/5ML | SOLUTION / ORAL | AA | RS | 2008-01-29 | 2680178bc6a6… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A040776-001 | DEXTROAMPHETAMINE SULFATE | 5MG/5ML | SOLUTION / ORAL | AA | RS | 2008-01-29 | 5bbf6a4d5a75… |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A040776-001 | DEXTROAMPHETAMINE SULFATE | 5MG/5ML | SOLUTION / ORAL | AA | RS | 2008-01-29 | d8e5a09893c0… |
| 2024-10-29 15:01 UTC | 2024-10 | A040776-001 | DEXTROAMPHETAMINE SULFATE | 5MG/5ML | SOLUTION / ORAL | AA | RS | 2008-01-29 | d06236e962d9… |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A040776-001 | DEXTROAMPHETAMINE SULFATE | 5MG/5ML | SOLUTION / ORAL | AA | RS | 2008-01-29 | 79d66fd596c7… |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A040776-001 | DEXTROAMPHETAMINE SULFATE | 5MG/5ML | SOLUTION / ORAL | AA | RS | 2008-01-29 | 301d65b070ca… |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A040776-001 | DEXTROAMPHETAMINE SULFATE | 5MG/5ML | SOLUTION / ORAL | AA | RS | 2008-01-29 | 1e350fbaab3a… |
| 2024-05-31 18:47 UTC | 2024-05 | A040776-001 | DEXTROAMPHETAMINE SULFATE | 5MG/5ML | SOLUTION / ORAL | AA | RS | 2008-01-29 | 8072bd15b7f6… |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A040776-001 | DEXTROAMPHETAMINE SULFATE | 5MG/5ML | SOLUTION / ORAL | AA | RS | 2008-01-29 | 5c6f7cd8ea54… |
| 2022-04-08 23:34 UTC | 2022-04 | A040776-001 | DEXTROAMPHETAMINE SULFATE | 5MG/5ML | SOLUTION / ORAL | AA | RS | 2008-01-29 | 5d02ea3f76ae… |
| 2022-04-04 05:41 UTC | 2022-04 | A040776-001 | DEXTROAMPHETAMINE SULFATE | 5MG/5ML | SOLUTION / ORAL | AA | RS | 2008-01-29 | 4b0b4de00fa7… |
| 2019-12-13 00:20 UTC | 2019-12 | A040776-001 | DEXTROAMPHETAMINE SULFATE | 5MG/5ML | SOLUTION / ORAL | AA | RS | 2008-01-29 | 74a2ff9319b5… |
| 2022-03-09 01:35 UTC | 2022-03 | A040776-001 | DEXTROAMPHETAMINE SULFATE | 5MG/5ML | SOLUTION / ORAL | AA | RS | 2008-01-29 | bb7c543d1eb4… |
| 2021-12-28 21:50 UTC | 2021-12 | A040776-001 | DEXTROAMPHETAMINE SULFATE | 5MG/5ML | SOLUTION / ORAL | AA | RS | 2008-01-29 | 782e0a99824c… |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A040776-001 | DEXTROAMPHETAMINE SULFATE | 5MG/5ML | SOLUTION / ORAL | AA | RS | 2008-01-29 | 87673890dc5c… |
| 2021-03-12 10:30 UTC | 2021-03 | A040776-001 | DEXTROAMPHETAMINE SULFATE | 5MG/5ML | SOLUTION / ORAL | AA | RS | 2008-01-29 | 5aa47cf7b7d7… |
| 2020-12-22 03:56 UTC | 2020-12 | A040776-001 | DEXTROAMPHETAMINE SULFATE | 5MG/5ML | SOLUTION / ORAL | AA | RS | 2008-01-29 | 8869cabd3fbd… |
| 2020-11-12 02:37 UTC | 2020-11 | A040776-001 | DEXTROAMPHETAMINE SULFATE | 5MG/5ML | SOLUTION / ORAL | AA | RS | 2008-01-29 | c0c555d07b60… |
| 2019-12-14 00:12 UTC | 2019-12 | A040776-001 | DEXTROAMPHETAMINE SULFATE | 5MG/5ML | SOLUTION / ORAL | AA | RS | 2008-01-29 | 3f01610625f2… |
| 2019-09-15 20:21 UTC | 2019-09 | A040776-001 | DEXTROAMPHETAMINE SULFATE | 5MG/5ML | SOLUTION / ORAL | AA | RS | 2008-01-29 | b00525d2431f… |
| 2019-07-19 19:46 UTC | 2019-07 | A040776-001 | DEXTROAMPHETAMINE SULFATE | 5MG/5ML | SOLUTION / ORAL | AA | RS | 2008-01-29 | ea99ee380514… |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | A040776-001 | DEXTROAMPHETAMINE SULFATE | 5MG/5ML | SOLUTION / ORAL | AA | RS | 2008-01-29 | 6a51e52b5d6a… |
| 2024-02-18 07:12 UTC | 2024-02 | A040776-001 | DEXTROAMPHETAMINE SULFATE | 5MG/5ML | SOLUTION / ORAL | AA | RS | 2008-01-29 | 1c564ffb4f44… |
| 2023-12-20 04:57 UTC | 2023-12 | A040776-001 | DEXTROAMPHETAMINE SULFATE | 5MG/5ML | SOLUTION / ORAL | AA | RS | 2008-01-29 | ea1830bbd6c7… |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | A040776-001 | DEXTROAMPHETAMINE SULFATE | 5MG/5ML | SOLUTION / ORAL | AA | RS | 2008-01-29 | a72a2bbeb626… |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | A040776-001 | DEXTROAMPHETAMINE SULFATE | 5MG/5ML | SOLUTION / ORAL | AA | RS | 2008-01-29 | 9b2671bbb829… |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | A040776-001 | DEXTROAMPHETAMINE SULFATE | 5MG/5ML | SOLUTION / ORAL | AA | RS | 2008-01-29 | a67488948f0b… |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | A040776-001 | DEXTROAMPHETAMINE SULFATE | 5MG/5ML | SOLUTION / ORAL | AA | RS | 2008-01-29 | 3f0d92c62455… |
| 2023-05-13 08:27 UTC | 2023-05 | A040776-001 | DEXTROAMPHETAMINE SULFATE | 5MG/5ML | SOLUTION / ORAL | AA | RS | 2008-01-29 | 053a50430f4f… |
| 2023-01-26 05:58 UTC | 2023-01 | A040776-001 | DEXTROAMPHETAMINE SULFATE | 5MG/5ML | SOLUTION / ORAL | AA | RS | 2008-01-29 | 3bdfa0b2c4d7… |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | A040776-001 | DEXTROAMPHETAMINE SULFATE | 5MG/5ML | SOLUTION / ORAL | AA | RS | 2008-01-29 | 3a93d1ddd44b… |
| 2022-10-28 04:53 UTC | 2022-10 | A040776-001 | DEXTROAMPHETAMINE SULFATE | 5MG/5ML | SOLUTION / ORAL | AA | RS | 2008-01-29 | f41ea6bd6efb… |
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A040776-001 | AA | 1 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | A040776-001 | AA | 1 | caaa826d4ba7… |
| 2026-02-19 14:30 UTC | 2026-02 | A040776-001 | AA | 1 | 011fe1cb6892… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A040776-001 | AA | 1 | 31067a03dcf5… |
| 2025-08-23 18:47 UTC | 2025-08 | A040776-001 | AA | 1 | 6a471c1ec25d… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A040776-001 | AA | 1 | fd3edfee7708… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A040776-001 | AA | 1 | b8a1b40f171c… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A040776-001 | AA | 1 | 03ed91905a0d… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A040776-001 | AA | 1 | 2680178bc6a6… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A040776-001 | AA | 1 | 5bbf6a4d5a75… |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A040776-001 | AA | 1 | d8e5a09893c0… |
| 2024-10-29 15:01 UTC | 2024-10 | A040776-001 | AA | 1 | d06236e962d9… |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A040776-001 | AA | 1 | 79d66fd596c7… |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A040776-001 | AA | 1 | 301d65b070ca… |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A040776-001 | AA | 1 | 1e350fbaab3a… |
| 2024-05-31 18:47 UTC | 2024-05 | A040776-001 | AA | 1 | 8072bd15b7f6… |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A040776-001 | AA | 1 | 5c6f7cd8ea54… |
| 2022-04-08 23:34 UTC | 2022-04 | A040776-001 | AA | 1 | 5d02ea3f76ae… |
| 2022-04-04 05:41 UTC | 2022-04 | A040776-001 | AA | 1 | 4b0b4de00fa7… |
| 2019-12-13 00:20 UTC | 2019-12 | A040776-001 | AA | 1 | 74a2ff9319b5… |
| 2022-03-09 01:35 UTC | 2022-03 | A040776-001 | AA | 1 | bb7c543d1eb4… |
| 2021-12-28 21:50 UTC | 2021-12 | A040776-001 | AA | 1 | 782e0a99824c… |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A040776-001 | AA | 1 | 87673890dc5c… |
| 2021-03-12 10:30 UTC | 2021-03 | A040776-001 | AA | 1 | 5aa47cf7b7d7… |
| 2020-12-22 03:56 UTC | 2020-12 | A040776-001 | AA | 1 | 8869cabd3fbd… |
| 2020-11-12 02:37 UTC | 2020-11 | A040776-001 | AA | 1 | c0c555d07b60… |
| 2019-12-14 00:12 UTC | 2019-12 | A040776-001 | AA | 1 | 3f01610625f2… |
| 2019-09-15 20:21 UTC | 2019-09 | A040776-001 | AA | 1 | b00525d2431f… |
| 2019-07-19 19:46 UTC | 2019-07 | A040776-001 | AA | 1 | ea99ee380514… |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | A040776-001 | AA | 1 | 6a51e52b5d6a… |
| 2024-02-18 07:12 UTC | 2024-02 | A040776-001 | AA | 1 | 1c564ffb4f44… |
| 2023-12-20 04:57 UTC | 2023-12 | A040776-001 | AA | 1 | ea1830bbd6c7… |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | A040776-001 | AA | 1 | a72a2bbeb626… |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | A040776-001 | AA | 1 | 9b2671bbb829… |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | A040776-001 | AA | 1 | a67488948f0b… |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | A040776-001 | AA | 1 | 3f0d92c62455… |
| 2023-05-13 08:27 UTC | 2023-05 | A040776-001 | AA | 1 | 053a50430f4f… |
| 2023-01-26 05:58 UTC | 2023-01 | A040776-001 | AA | 1 | 3bdfa0b2c4d7… |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | A040776-001 | AA | 1 | 3a93d1ddd44b… |
| 2022-10-28 04:53 UTC | 2022-10 | A040776-001 | AA | 1 | f41ea6bd6efb… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| ece2fdfc-54b9-46e4-9357-ee94cf8e9d03 | 5bc88dc0-b6b2-4c3f-8ecb-03e41b085e1d | 2023-01-12 | Boxed warning, Warnings, Adverse reactions | 5bc88dc0-b6b2-4c3f-8ecb-03e41b085e1d |
Adverse event summaries are temporarily unavailable. Other product information remains available.